期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 16, 期 7, 页码 16576-16592出版社
MDPI
DOI: 10.3390/ijms160716576
关键词
multiple sclerosis; neuromyelitis optica; B cells; autoantibodies; autoantigen; pathogenesis; therapy
资金
- University of Basel and research
- Biogen Idec
- Merck Serono
- Bayer Schering Pharma
- Swiss National Research Foundation
- Novartis Pharma
- European Union
- Swiss MS Society
- Genzyme
- Mitsubishi Pharma
- TEVA Pharma
- GeNeuro
While over the past decades T cells have been considered key players in the pathogenesis of multiple sclerosis (MS), it has only recently become evident that B cells have a major contributing role. Our understanding of the role of B cells has evolved substantially following the clinical success of B cell-targeting therapies and increasing experimental evidence for significant B cell involvement. Rather than mere antibody-producing cells, it is becoming clear that they are team players with the capacity to prime and regulate T cells, and function both as pro- and anti-inflammatory mediators. However, despite tremendous efforts, the target antigen(s) of B cells in MS have yet to be identified. The first part of this review summarizes the clinical evidence and results from animal studies pointing to the relevance of B cells in the pathogenesis of MS. The second part gives an overview of the currently known potential autoantigen targets. The third part recapitulates and critically appraises the currently available B cell-directed therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据